FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per resp	onse: 0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Goldstein Dan Requiring (Month/D			2. Date of Even Requiring State (Month/Day/Yea 04/07/2016	ment	3. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]						
(Last)	(First)	(Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			(M	5. If Amendment, Date of Original Filed (Month/Day/Year)		
					X	Officer (give title below)	Other (spec below)		ndividual or Joint plicable Line)	/Group Filing (Check	
(Street) BRAINTREE	MA	02184				Chief Accounting	Officer			y One Reporting Person y More than One erson	
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					nt of Securities ally Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock						2,397(1)	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable a Expiration Date (Month/Day/Year) Date Exercisable Expiration Date Exercisable Date		ate		e and Amount of Securiti rlying Derivative Security		4. Conversio or Exercis	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
				Expiration Date	1 Title		Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Non-qualified S	Stock Option ((Right to Buy)	04/06/2017	04/06/2023	3	Common Stock	10,428(2)	34.42	D		

Explanation of Responses:

- 1. Mr. Goldstein was appointed Chief Accounting Officer April 7, 2016. This grant was made in connection with his appointment and represents Restricted Stock Units which vest 25% per year over 4 years following the grant date.
- 2. Non-qualified stock option grant providing a right to buy shares of common stock exercisable in annual increments of 25% beginning on the first anniversary of the date of grant.

/s/ Alexander P. Steffan,

attorney-in-fact for Mr. 11/15/2017

Goldstein

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Haemonetics Corp

Power of Attorney for Executing Forms 3, 4 and 5

Know all men by these presents, that the undersigned, director or officer, or both, of Haemonetics Corp, hereby constitutes and appoints each of Alexander P. Steffan, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Haemonetics Corp (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities of Haemonetics Corp unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of this 27th day of July, 2017

/s/ Dan Goldstein

Dan Goldstein